We are live on ! Find out more
HAE icon

Haemonetics

312 hedge funds and large institutions have $3.44B invested in Haemonetics in 2025 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 128 increasing their positions, 100 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more call options, than puts

Call options by funds: $26M | Put options by funds: $20.1M

28% more repeat investments, than reductions

Existing positions increased: 128 | Existing positions reduced: 100

2% more funds holding

Funds holding: 307 → 312 (+5)

6% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 47

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

2.63% less ownership

Funds ownership: 110.5% → 107.87% (-2.6%)

27% less capital inflows, than outflows

Capital inflows: $479M | Capital outflows: $660M

Holders
312
Holders Change
+5
Holders Change %
+1.63%
% of All Funds
4.17%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
50
Increased
128
Reduced
100
Closed
47
Calls
$26​M
Puts
$20.1​M
Net Calls
+$5.9​M
Net Calls Change
+$5.14​M

HAE Hedge Fund Activity: Q1 2025 in Review

312 of the 7,490 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2025, worth a combined $3.44B — down 22% from $4.42B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new HAE positions and 47 closed out — a net gain of 3 holders — while 128 added to existing stakes and 100 trimmed.

The largest buyer was River Road Asset Management, opening a new position worth an estimated $94.9M. The largest seller was Capital Research Global Investors, cutting an estimated $181M.

  • 312 institutional investors held Haemonetics (HAE) as of Q1 2025, up from 307 in Q4 2024.
  • Funds reported $3.44B of Haemonetics stock for Q1 2025, down 22% quarter-over-quarter.
  • 50 funds opened new Haemonetics positions in Q1 2025 and 47 closed out, a net change of +3 holders.
  • The largest Haemonetics buyer in Q1 2025 was River Road Asset Management, an estimated $94.9M added.
  • The largest Haemonetics seller in Q1 2025 was Capital Research Global Investors, an estimated $181M sold.

Based on aggregated 13F filings for Q1 2025.